ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
This video was recorded during the ESC Congress 2024 in London, UK.
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024
ESC 2024 - In OCEANIC-AF, the effects of the novel factor XIa inhibitor asundexian versus apixaban were evulated in patients with AF at high stroke risk. Manesh Patel discusses the study results.
This video was recorded during the ESC Congress 2024 in London, UK.
Manesh Patel is a cardiologist at Duke Hospital in Durham, NC, US.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of OCEANIC-AF
Release date: 2 September 2024
Stay current with the best on medical education
